论文部分内容阅读
目的:监测拉米夫定抗病毒治疗的乙型肝炎患者血清中的乙型肝炎病毒大蛋白(HBV-LP)和乙型肝炎病毒DNA(HBV-DNA)载量,探讨拉米夫定治疗过程中HBV-LP与HBV-DNA的关系,观察乙型肝炎病毒大蛋白用于评估拉米夫定抗病毒治疗效果的应用效果。方法:采用酶联免疫吸附试验(ELISA)的方法检测HBV-LP;采用荧光定量PCR方法对HBV-DNA进行检测。结果:47例患者接受拉米夫定抗病毒治疗12个月后HBV-DNA、HBV-LP两个检测指标阴转率无明显差别,HBV-LP转阴时间比HBV-DNA晚3~6个月;抗病毒治疗过程中,HBV-DNA和HBV-LP均呈下降趋势有较高的相关性,r=0.81,P<0.01。结论:拉米夫定抗病毒治疗过程中动态检测乙型肝炎病毒大蛋白可用于评估抗病毒治疗效果。
OBJECTIVE: To monitor the serum levels of hepatitis B virus (HBV-LP) and hepatitis B virus (HBV-DNA) in hepatitis B patients treated with lamivudine antiviral therapy and explore the influence of lamivudine treatment HBV-LP and HBV-DNA, and to observe the effect of hepatitis B virus large protein in evaluating the effect of lamivudine antiviral therapy. Methods: HBV-LP was detected by enzyme linked immunosorbent assay (ELISA); HBV-DNA was detected by fluorescence quantitative PCR. Results: There was no significant difference in the negative conversion rate of HBV-DNA and HBV-LP after 47 months of treatment with lamivudine in HBV-LP, and the negative conversion rate of HBV-LP was 3 to 6 Month; there was a high correlation between HBV-DNA and HBV-LP in anti-viral therapy, r = 0.81, P <0.01. Conclusion: Dynamic detection of hepatitis B virus large protein during lamivudine antiviral therapy can be used to evaluate the effect of antiviral therapy.